Total Syntheses of (±)-Platencin and (−)-Platencin

K. C. Nicolaou[*], **G. Scott Tria**, **David J. Edmonds**, and **Moumita Kar**
Contribution from the Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, and the Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093

Abstract

The secondary metabolites platensimycin (**1**) and platencin (**2**), isolated from the bacterial strain *Streptomyces platensis*, represent a novel class of natural products exhibiting unique and potent antibacterial activity. Platencin, though structurally similar to platensimycin, has been found to operate through a slightly different mechanism of action involving the dual inhibition of lipid elongation enzymes FabF and FabH. Both natural products exhibit strong, broad-spectrum, Gram-positive antibacterial activity to key antibiotic resistant strains, including methicillin-resistant *Staphylococcus aureus*, vancomycin-intermediate *S. aureus*, and vancomycin-resistant *Enterococcus faecium*. Described herein are our synthetic efforts toward platencin, culminating in both the racemic and asymmetric preparation of the natural product. The syntheses demonstrate the power of the cobalt-catalyzed asymmetric Diels–Alder reaction and the one-pot reductive rearrangement of [3.2.1] bicyclic ketones to [2.2.2] bicyclic olefins.

Introduction

The initial euphoria associated with the discovery and development of penicillin was soon dampened by the realization that bacteria could evade its lethal activity through their ability to replicate and evolve rapidly into drug-resistant strains. The problems caused by bacterial drug-resistance have been exacerbated by overuse and often misuse of antibiotics. Thus, in 1941, when penicillin was first introduced, virtually all strains of *Staphylococcus aureus* were susceptible to the novel antibiotic, but by 1944 many strains had developed resistance by evolving enzymes (*e.g.* β-lactamase) capable of destroying the drug before it could reach its biological target.[1] For a time, science and medicine were able to stay ahead of these menacing organisms by modifying existing antibiotics, but by the end of the twentieth century humanity was faced with alarming challenges from drug-resistant bacteria. For example, a recent study estimated 94,360 cases of invasive methicillin-resistant *S. aureus* (MRSA) occurred in the United States in 2005, with 18,650 of them resulting in death.[2] Although the majority of such cases occur in hospital facilities there has been a significant rise in the number of reported community-acquired infections. This concerning state of affairs led to a renewed surge in research activities to discover and develop new antibiotics to combat the increasing threat of bacterial resistance.

Fatty acid biosynthesis, an essential process for the survival and propagation of bacteria, is the primary means by which bacteria form fatty acids necessary for energy storage and cellular structure building blocks. This, along with the significant differences between the human and

bacterial fatty acid biosynthetic machinery, makes the bacterial fatty acid synthase (FAS) pathway an attractive strategy in the against drug-resistant bacteria.[3,4] Taking advantage of modern biological techniques, a Merck team recently developed an antisense silencing RNA based assay for identifying inhibitors of the type II fatty acid biosynthesis (FAS II) pathway present in bacterial cells.[3] The gene encoding the FabH and FabF condensing enzymes of FAS II was silenced, sensitizing the bacteria to inhibitors of these enzymes, and allowing for a high-throughput, whole cell, target-based assay. Screening of 250,000 natural product extracts ultimately led to the discovery of the dual FabF/FabH inhibitor platencin (**1**) and its congener platencin A$_1$,[5] along with the selective FabF inhibitor platensimycin (**2**).[6]

Platensimycin, isolated from *Streptomyces platensis* MA 7327, was discovered in a soil sample collected in Eastern Cape, South Africa, while platencin, isolated from *S. platensis* MA 7339, was found in a soil sample collected in Mallorca, Spain. The two antibiotics include in their structures the 3-amino-2,4-dihydroxy benzoic acid structural motif but differ in their more hydrophobic ketolide portion. Platensimycin consists of a tetracyclic framework that contains a cyclic ether, whereas platencin features an exclusively carbocyclic framework with only three rings. Like its sibling, platencin exhibits potent and broad *in vitro* and *in vivo* antibiotic activity against Gram-positive bacteria, including activity against a variety of drug-resistant bacteria such as methicillin-resistant *S. aureus* (MRSA, 1 μg/mL vs. 0.5 μg/mL for platensimycin) and vancomycin-resistant *Enterococcus faecium* (VREF, < 0.06 μg/mL vs. 0.01 μg/mL for platensimycin). Platencin also exhibited comparable *in vivo* efficacy in a continuous infusion mouse model against *S. aureus* infection with no indication of toxicity. As might be expected from their close structural relationship, platencin and platensimycin operate through a similar mechanism of action. Each was shown to inhibit lipid biosynthesis in whole cell labeling studies, but neither exhibited any activity against nucleic acid, protein biosynthesis or cell wall construction. At a molecular level, platensimycin is a potent and selective inhibitor of FabF, the elongation condensing enzyme; however, platencin inhibits this enzyme with much lower potency. Platencin derives its overall potency from a dual inhibition mechanism involving moderate inhibition of both FabF and the initiation condensing enzyme FabH.[5] It should be noted that a recent report questioned the validity of the strategy to combat bacteria based on fatty acid biosynthesis since bacteria were found to sequester the needed fatty acids from their hosts.[4]

The structural novelty and potent activity of these antibiotics has attracted considerable attention, with a number of total syntheses of platensimycin[7] and platencin[8] reported to date. Several reports have also described the design and synthesis of related structures,[9] some of which are also potent antibiotics.[9a,b,d,f] In 2008, we published our preliminary results culminating in the first total synthesis of platencin (**1**) through an asymmetric route.[8a] Herein we present the full account of our work in this area that led to considerable improvements of the originally developed route.

Results and Discussion

Our total synthesis endeavors toward platencin, first as a racemate, and then in its enantiomerically pure form, proceeded through a number of phases and evolved into a highly efficient and streamlined process. Below we describe these studies in approximately the chronological sequence they occurred.

Initial Retrosynthetic Analysis

Figure 2 shows our retrosynthetic analysis of **1**. Only a cursory inspection of the platencin molecule was needed to identify the first retrosynthetic disconnection, that of the amide bond, which revealed fragments **3** and **4** as potential precursors. Aniline derivative **3** was thought to be the ideal precursor for reasons of convenience and practicality given the expected sensitivity

of the exocyclic olefinic bond of the final product and the neutral conditions under which the TMSE group could be removed. Applying two consecutive retrosynthetic alkylations on tricyclic fragment **4** led to enone **5** as the required key intermediate for the ketolide domain of the molecule. The latter was envisioned to arise from a ketoaldehyde, derived from **6** (R = H or protecting group) through an aldol condensation. A radical pathway starting from xanthate **9a** or hydrazone **12**, and proceeding through species **8** (R = H or protecting group) and **7** (R = H or protecting group) was then traced based on a homoallylic radical rearrangement.[10] Our initial analysis adopted xanthate **9a** as the potential precursor of the first radical species of the envisioned cascade and connected it to ketone **10**. Disconnection of the indicated carbon-carbon bonds within [3.2.1] bicyclic system **10** through a retro conjugate addition of an allyl group and a retro palladium-catalyzed cyclization revealed enol ether **11** as a potential precursor.[10a] The latter intermediate was then traced back to hydroxymethyl enone **15** as a starting material. Our plan makes use of a hydrazone radical precursor of type **12**, which can be traced through a similar retrosynthetic sequence, employing a gold(I)-catalyzed cyclization[11] of an enol ether such as **14** and leading back to acetylenic hydroxymethyl enone **16**.

First Generation Synthesis of Racemic Tricyclic Enone (±)-5

As part of our preliminary studies toward platencin (**1**), we explored the xanthate-based homoallylic rearrangement route to tricyclic ketone (±)-**5** using racemic materials (Scheme 1).

Thus, treatment of enone **17** with LiHMDS in THF at −78 °C followed by addition of Mander's reagent (MeOCOCN)[12] gave the corresponding carboxymethylated product which was allylated to afford compound (±)-**18** in 73% overall yield. Reduction of the latter with LiAlH$_4$ followed by acidic (aq. HCl) workup led to enone (±)-**15** (82% yield), the free hydroxyl group of which was protected as a PMB ether to afford (±)-**19** (85% yield). Treatment of ketone (±)-**19** with TBSOTf in the presence of Et$_3$N led to the corresponding TBS enol ether (91% yield), which underwent smooth oxidative cycloalkenylation upon exposure to a catalytic amount of Pd(OAc)$_2$ under an atmosphere of O$_2$ to afford bicyclic system (±)-**20** in 85% yield, along with traces of the endocyclic olefinic by-product. Copper-catalyzed conjugate addition of allyl magnesium chloride to (±)-**20** (CuBr•Me$_2$S, −78 → −40 °C) gave ketone (±)-**10** in 86% yield as a single diastereoisomer. Sodium borohydride reduction of (±)-**10** gave a mixture of corresponding alcohols (97% yield, *ca.* 2:1 d.r.) that was converted to xanthates (±)-**9a** by the standard procedure.[13] Generation of the radical species from (±)-**9a** by treatment with *n*-Bu$_3$SnH-AIBN in toluene at 110 °C led to the desired [2.2.2] bicyclic product (±)-**6a** in excellent yield (92%), although the latter was contaminated with by-product **21a** (*ca.* 4:1 ratio), arising from the alternative mode of cyclization (5-*exo*-trig, path b). The individual xanthate diastereomers obtained from the diastereomerically pure alcohol precursors gave identical results, confirming that the stereochemistry of the radical precursor was inconsequential to the outcome of the reaction with regard to both yield and product distribution. The mixture of (±)-**6a** and **21a** was inseparable by chromatography, but Wacker oxidation[14] furnished ketone (±)-**21** (81% yield), which was easily separated from the unreactive byproduct **21a**. The product obtained by DDQ deprotection of PMB-protected intermediate (±)-**21** (53% yield) was found to exist in its lactol form [(±)-**22**], a fact that did not deter its oxidation to keto aldehyde (±)-**23** [NMO, TPAP (cat.), 54% yield].[15] Furthermore, the intended aldol condensation of (±)-**23** to racemic enone (±)-**5** proceeded under the influence of NaOH in ethanol in excellent yield, demonstrating the viability of this radical-based strategy for the synthesis of platencin. As additional intelligence, this initial study provided useful information regarding the stability of the PMB protecting group, the performance of which, in a number of steps, particularly the Wacker oxidation, was less than stellar, prompting us to consider a more robust alternative for our first asymmetric approach to enone **5**.

Asymmetric Synthesis of Enone (+)-5

In contemplating an asymmetric version of the radical rearrangement approach to enone (±)-**5** we sought to prepare an enone such as **15** or **16** (Figure 2) as single enantiomers, in the knowledge that all the other centers could then be set through substrate control. One approach would be to effect an asymmetric variant of the alkylation reaction used to prepare ketoester (±)-**18** (Scheme 1). Palladium-catalyzed asymmetric allylation[16] reactions of similar ketoesters and their derivatives have been described in the literature;[17,18] however, factors including unsatisfactory *ee* in our system, lack of readily available catalysts (particularly for large scale use), and the fact that any such approach would be limited to the introduction of an allyl substituent, led us to favor an asymmetric Diels–Alder reaction strategy.[19] Asymmetric alkylation reactions using chiral bases or chiral phase transfer catalysts were also considered but not pursued for similar perceived drawbacks.

Rawal and coworkers have described the asymmetric Diels–Alder reaction of substituted 1-amino-3-silyloxybutadienes using the Jacobsen Cr(III)-salen catalyst.[20] This system appeared attractive for our purposes since it was reported to offer access to highly enantiomerically enriched 4,4-disubstituted cyclohexenones. The application of this reaction to the asymmetric synthesis of **16** (Figure 2) required diene **26** and dienophile **30**, the syntheses of which are summarized in Scheme 2.

Diene **26** was prepared from commercially available ketone **24** according to literature procedures,[21] while the rather volatile dienophile **30** was synthesized from acetylenic alcohol **27** in one pot through a two-step process involving oxidation (py•SO$_3$, DMSO)[22] and addition of Eschenmoser's salt (**29**, 53% overall yield).[23] Reaction of diene **26** (excess) with dienophile **30** (Scheme 3) in the presence of 0.05 mol% catalyst **32** (Figure 4) at −60 °C resulted in an impressive 92% yield of cyclohexene (−)-**33**, formed in 93% *ee* [determined by ^{1}H NMR spectroscopic analysis of the Mosher ester derived from downstream product (−)-**16**]. We subsequently realized that the enantioselectivity of this reaction ranged between 85 and 93% *ee*, presumably due to its sensitivity to temperature and the difficulties in maintaining a steady cryogenic temperature for the extended reaction time (60 h). This deficiency, coupled to the poor reproducibility of the results on larger scales, prompted subsequent studies that resulted in considerable improvements, as discussed later. Returning to Diels–Alder product (−)-**33**, it was found that its intended conversion to enone (−)-**16** (Scheme 3) could be achieved by reduction with LiAlH$_4$ followed by exposure of the resulting hydroxy carbamate (**34**) to aqueous acid (63% overall yield).

At this stage we selected the SEM group to protect the primary hydroxyl group in place of the PMB group used previously, by virtue of its robustness and linear shape, which we reasoned would not hinder any of the subsequently intended steps. Thus, treatment of (−)-**16** with SEMCl in the presence of Et$_3$N and 4-DMAP (cat.) furnished derivative (−)-**35** (94% yield), which was converted to TIPS diene (−)-**36** (TIPSOTf, Et$_3$N, 97% yield) in preparation for the crucial cycloalkenylation reaction. To this end, acetylenic enol ether (−)-**36** was exposed to the action of the cationic gold catalyst formed *in situ* from AuCl(PPh$_3$) and AgBF$_4$, conditions that led, within 30 min at room temperature, to the desired bicyclic enone (+)-**37** in 94% yield.[11] Note that our initial study toward this type of [3.2.1] bicyclic system involved a palladium-catalyzed cycloalkenylation process of a similar substrate containing a terminal olefin rather than the terminal acetylene contained within (−)-**36** [*i.e.* (±)-**19** → (±)-**20**, Scheme 1]. In contrasting the two processes, one can easily recognize the advantage of the latter method in terms of catalyst loading (2% gold catalyst vs. 10% palladium catalyst), reaction time (< 30 min at 25 °C vs. 12 h at 45 °C), and yield (94% vs. 85%). Conjugate addition of an allyl group to enone (+)-**37** (allyl MgCl, CuBr•Me$_2$S) proceeded smoothly to afford ketone (+)-**38** as a single diastereomer in 74% yield. Ketone (+)-**38** was converted, as before, to a mixture of xanthates (−)-**9b** (*ca.* 2:1 d.r.) by the standard two-step sequence (NaBH$_4$; KHMDS, CS$_2$, MeI) in 97%

overall yield. The radical rearrangement sequence of (−)-**9b** proceeded as before, giving a high yield of diene **6b** (92%), along with a minor quantity of byproduct **21b**.[24] Wacker oxidation also proceeded as expected to provide ketone (−)-**39** in 50% overall yield from (−)-**9b**, however, the removal of the SEM group proved difficult. A systematic investigation of conditions identified nucleophilic fluoride sources as the only reagents capable of delivering the desired product, with TASF in DMPU being the optimum choice, giving up to 63% yield of lactol (−)-**22** along with *ca.* 25% recovered starting material (−)-**39**. Interestingly, lactol (−)-**22** was isolated as a single diastereoisomer regardless of which precursor was used. This compound crystallized from $CDCl_3/CH_2Cl_2$ as colorless needles (m.p. 115–117 °C), a circumstance that allowed its X-ray crystallographic analysis (see ORTEP drawing, Figure 3) and, thus, confirmed its structure as depicted in (−)-**22**.[25] The subsequent oxidation and aldol condensation steps proceeded well, as before, to afford enantiomerically enriched tricyclic enone (+)-**5** as shown in Scheme 3.

Optimization of the Catalytic Asymmetric Synthesis of Enone (+)-5

The asymmetric synthesis of enone (+)-**5** described above proved effiecient enough to allow us to complete the total synthesis of platencin [(−)-**1**] in a highly enantioenriched form (*vide infra*);[8a] however, we identified several opportunities to improve the route at several steps while maintaining the overall strategy. These included asymmetric Diels–Alder reaction, the radical rearrangement sequence, and the protecting group choice. We were able to optimize each of these processes, which, in turn, influenced the overall efficiency of the synthesis, leading to an effective and streamlined route.

A significant practical drawback in our original asymmetric route is the volatility of dienophile **30**. This enal was prepared in a highly efficient one-pot procedure that provided the product in excellent purity, but the isolated yield was only moderate, even when solvents were removed by careful distillation through a Vigreaux column. This issue was addressed by the simple inclusion of a TMS group on the alkyne. TMS-capped enal **31** was prepared from commercially available acetylene **28** using the same one-pot procedure and could be isolated by flash column chromatography or distillation in 92% yield as shown in Scheme 2. We investigated the use of both dienophiles during optimization studies to improve the practicality of the asymmetric Diels–Alder reaction with the previously discussed Cr(III)-based catalyst (**32**) as well as a similar Co(III)-based system (**40**, Figure 4).

In these investigations we were guided by the findings of the Rawal group in their development of asymmetric Diels–Alder reactions of aminosilyloxy dienes;[26] our results are summarized in Table 1.

We were able to optimize the reaction of our original dienophile (**30**) with diene **26** and chromium catalyst **32** (entries 1–3) to 92% yield and 93% *ee*, although, as mentioned above, the reaction was very slow and somewhat unreliable with respect to the *ee* of the product. The use of cobalt-salen catalyst **40** (entry 4) with dienophile **30** resulted in a much faster reaction at the expense of reduced *ee* and somewhat reduced yield; however, changing to dienophile **31** brought significant improvements. We tentatively ascribe this observation to the improved purity of the less volatile dieneophile. Further study of the cobalt-catalyzed reaction of **31** with **26** led to the optimized conditions (entry 7), which use only a slight excess of diene and give an almost quantitative yield of product (−)-**41** with excellent enantioselectivity (96% *ee*). Noteworthy features of the Diels–Alder reaction using catalyst **40** and dienophile **31** include the much increased reaction rate (0.5 h vs. 60 h with catalyst **32**) and the improved selectivity at more convenient temperatures (0 °C vs –60 °C). We also observed that the Diels–Alder reaction between dienophile **31** and diene **26** proceeded to some extent at ambient temperature in the absence of any catalyst (entry 8).

We next turned our attention to the radical rearrangement reaction. This reaction performed as expected in our original route, but the three step conversion of ketone (±)-**10** or (+)-**38** to (±)-**6a** (Scheme 1) or **6b** (Scheme 3) involved the use of toxic reagents in both the radical and xanthate formation steps, and suffered from the formation of small but significant quantities of the 5-*exo*-trig byproducts. At this time, we were also investigating the optimum protecting group for the primary alcohol, which led to an interesting observation. When testing the radical sequence using substrates with various protecting groups, we noted that the pathway of the radical process was dependent on the nature of the protecting group used (Table 2). When smaller, linear protecting groups, such as MOM or SEM, were used, the radical sequence proceeded to give the desired [2.2.2] bicyclic products (**6a–e**) with good selectivity over the 5-*exo*-trig by-products (entries 1 and 2); the PMB ether gave similar selectivity affording an approximately 4:1 mixture (entry 3). However, both acetate and pivalate esters yielded significantly lower selectivities affording approximately 1:2 mixture of the two products (entries 4 and 5), indicating the finely balanced nature of the selectivity between the two competing reaction manifolds. Presumably, steric interactions of the ester groups position the olefinic moiety of the allyl group in such a way so as to favor the 5-*exo*-trig pathway leading to the undesired by-products **21a–e**.

In an effort to streamline the overall conversion of the ketone intermediate to the radical rearrangement product, we explored the Wolff–Kishner type conditions for radical generation from carbonyl compounds reported by Toyota *et al.*[27] Table 3 summarizes our optimization studies using several hydrazone intermediates prepared from the corresponding ketones [TsNHNH$_2$, TsOH (cat.), CH$_2$Cl$_2$, 70 °C]. Our initial attempts to apply the reported NaBH$_3$CN/ZnCl$_2$ conditions[27a] to hydrazones **12a–c** (entries 1–3) failed to furnish any of the desired products, leading only to decomposition. Reasoning that the Lewis acid conditions employed were responsible for the observed outcome, we attempted the reaction with the SEM-protected hydrazone **12d** employing NaBH$_4$ in THF (entry 4), but again observed only decomposition. Use of the milder reductant NaBH(OAc)$_3$ was also unsuccessful leading, this time, to recovery of the starting material (entry 5). Further studies led us to return to NaBH$_4$ as a potential reductant in a variety of solvents. Our efforts were rewarded when we employed hydrazone **12d** and NaBH$_4$ in refluxing CH$_2$Cl$_2$:MeOH (1:1), conditions that led to 50% yield of the desired product (−)-**6b** (entry 6). These conditions were then optimized (entries 8–11) to a satisfactory level (entry 11), which required portionwise addition of NaBH$_4$ to a refluxing solution of hydrazone **12d** in CH$_2$Cl$_2$:MeOH [20:1, 70% yield of (−)-**6b**]. Furthermore, by avoiding the need for a xanthate formation step, we were able to employ the hydroxy hydrazone **12** (R = H) to produce rearranged product (−)-**6** (R = H) under the same optimized conditions in 74% yield (Table 3, entry 12).

Our optimized Diels–Alder and radical rearrangement steps were then combined to furnish our second generation asymmetric synthesis of key enone intermediate (+)-**5** (Scheme 4). Thus, following the asymmetric Diels–Alder reaction of **26** with **31**, product (−)-**41** was converted to hydroxy enone (−)-**16** in a one-pot procedure involving reduction of the aldehyde (LiAlH$_4$, Et$_2$O-THF), cleavage of the acetylenic TMS group by addition of MeOH and K$_2$CO$_3$, and, finally, elimination of the carbamate group by acidification with methanolic HCl. Hydroxy enone (−)-**16** was obtained in 89% overall yield and 96% *ee*. A single recrystallization of the product from hexanes:EtOAc (m.p. 100–102 °C) increased the *ee* to > 98% *ee*. In preparation for the gold-catalyzed cyclization, we attempted to generate the bis-TBS derivative (−)-**14** from hydroxyl enone (−)-**16** by exposure of the latter to TBSOTf and Et$_3$N. Although a smooth reaction under these conditions was observed by TLC, upon workup only starting material was recovered. Closer monitoring and NMR spectroscopic analysis of the reaction mixture in CDCl$_3$ revealed the formation of bicyclic ketal **44** (see Scheme 5), which apparently is stable under the reaction conditions, but immediately reverts back to starting material [(−)-**16**] upon workup. To circumvent this troublesome circumstance we employed a one-pot

protocol involving sequential treatment of hydroxyl enone (−)-**16**, first with TBSCl in the presence of Et_3N and 4-DMAP (capping the hydroxyl group), followed by TBSOTf (forming the TBS enol ether), conditions that led to generation of the desired bis-TBS derivative (−)-**14** in 97% yield. This material was then subjected to the gold-catalyzed ring closure conditions [2 mol% $Au(PPh_3)$, 2 mol% $AgBF_4$] to produce bicyclic enone (+)-**42** in 95% yield (Scheme 4). Exposure of enone (+)-**42** to allylmagnesium bromide in the presence of CuBr•SMe_2 at −78 → −40 °C, followed by acidic workup (aq. HCl), led to intermediate (+)-**13** in 85% overall yield, thus avoiding either specific protection or deprotection steps.

Conversion of keto alcohol (+)-**13** to bicyclo [2.2.2] octane system (−)-**6** was easily achieved without the need to isolate intermediate hydrazone **12** (Scheme 4). Thus, formation of the hydrazone in CH_2Cl_2 with $TsNHNH_2$ and 0.1 mol% TsOH, followed by addition of MeOH and reduction as previously described, furnished (−)-**6** in 74% overall yield. The alcohol was then oxidized to aldehyde (−)-**43** with DMP and the latter compound was subjected to Wacker oxidation [$PdCl_2$ (cat.), CuCl, O_2] to afford keto aldehyde (−)-**23** in 90% yield, thus obviating the troublesome SEM deprotection and avoiding the intermediacy of lactol (−)-**22**. Finally, exposure of (−)-**23** to NaOH in EtOH as before furnished tricyclic enone (+)-**5** in 99% yield.

Synthesis of Carboxylic Acid Coupling Partner (+)-4

Having developed a streamlined and practical catalytic asymmetric route to the platencin core (+)-**5**, we turned our attention to the introduction of the appendages required for the carboxylic acid coupling partner (+)-**4**. We initially applied our sequence originally used for the corresponding platensimycin carboxylic acid, involving sequential alkylations and metathesis as shown in Scheme 6.[7a] Thus, enone (+)-**5** was methylated [KHMDS, MeI, THF:HMPA (4:1), −78 → 0 °C, 90% yield] to afford methyl enone (−)-**45** (*ca.* 10:1 d.r.), which was subjected to a second alkylation with allyl iodide (KHMDS, allyl iodide, THF:HMPA (4:1), −78 → 0 °C, 86% yield, single diastereomer) to give triene (+)-**46**. The latter compound was converted to the desired carboxylic acid (+)-**4** through a three-step procedure involving cross metathesis with boronate **48**[28] in the presence of Hoveyda–Grubbs catalyst **49**[29] and benzoquinone,[30] oxidation of the resulting vinyl boronate with Me_3NO to the corresponding aldehyde, and Pinnick oxidation of the latter, in 39% overall yield.[31]

In a separate attempt to access the carboxylic acid (+)-**4** from methylated enone (−)-**45**, and inspired by Corey's platensimycin analogue work,[9d] we subjected this compound to enolate formation (KO*t*-Bu) in the presence of methyl acrylate. However, we were disappointed to observe both modest yield of the desired methyl ester product along with a number of undesired by-products (10 → 0 °C). We then resorted to the use of *tert*-butyl acrylate (less prone to polymerization than its methyl counterpart under the reaction conditions) at ambient temperature and realized a 92% yield of the targeted product [(+)-**50**, Scheme 7], albeit in *ca*. 2:1 d.r. favoring the desired stereoisomer, which was chromatographically separated and fully characterized. The required cleavage of the *t*-butyl ester from the latter compound demanded basic conditions [LiOH (1 N aqueous):MeOH (1:1), 50 °C, 97% yield] as the exocyclic double bond was prone to isomerization and further destructive side-reactions under acidic conditions (*i.e.* TFA).

Preparation of Aniline Coupling Partner and Completion of the Total Synthesis of (−)-Platencin

The susceptibility of the core structural motif of platencin to acidic conditions dictated modification of the sequence originally employed in our total synthesis of platensimycin.[7a] Thus, aniline partner **3** (Scheme 8) equipped with a TMSE group was designed as a suitable coupling partner with carboxylic acid (+)-**4** due to the mild conditions under which we expected to carry our the final deprotection (−TMSE).

The preparation of this partner proceeded from the readily available nitro methyl ester (**51**) through ester exchange (*n*-Bu$_2$SnO, TMSCH$_2$CH$_2$OH, 70 °C, 61% yield)[32] and reduction (H$_2$, 10% Pd/C, quantitative) of the resulting product, as shown in Scheme 8. The coupling of carboxylic acid (+)-**4** with aniline derivative **3** proceeded under the influence of HATU and Et$_3$N in DMF at ambient temperature to give protected platencin (−)-**52**, in 61% yield, from which the TMSE group was removed through the action of TASF (40 °C, 93% yield). Synthetic (−)-platencin [(−)-**1**] crystallized from acetone/hexanes in cubic colorless crystals (m.p. 194–197 °C dec.) upon prolonged standing. Its X-ray crystallographic analysis (see ORTEP drawing, Figure 5)[33] unambiguously confirmed its structure, and, therefore, that of the natural substance, whose X-ray crystallographic analysis has not been previously reported.

Conclusion

The described chemistry provides a streamlined asymmetric approach to the newly reported antibiotic platencin and its analogues. The developed synthetic strategies delivered both the racemic [(±)-**1**] and naturally occurring [(−)-**1**] forms of the natural product and allowed for the first X-ray crystallographic analysis of this antibiotic. Demonstrated by this synthesis are the power of the cobalt-catalyzed asymmetric Diels–Alder reaction[26] and the one-pot reductive rearrangement of [3.2.1] bicyclic ketones to [2.2.2] bicyclic olefins through their hydrazones.[27] Further applications of these synthetic technologies in chemical synthesis are foreseen.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

References

1. Neu HC. Science 1992;257:1064. [PubMed: 1509257]

2. Klevens RM, et al. J Am Med Assoc 2007;298:1763.

3. For an excellent overview of this program, see: (a) Singh SB, Phillips JW, Wang J. Curr Opin Drug Disc Dev 2007;10:160. (b) Young K, et al. Antimicrob Agents Chemother 2006;50:519. [PubMed: 16436705]

4. Brinster S, Lamberet G, Staels B, Trieu-Cuot P, Gruss A, Poyart C. Nature 2009;458:83. [PubMed: 19262672]

5. For isolation of platencin, see: (a) Wang J, et al. Proc Natl Acad Sci USA 2007;104:7612. [PubMed: 17456595] (b) Jayasuriya H, Herath KB, Zhang C, Zink DL, Basilio A, Genilloud O, Teresa Diez M, Vicente F, Gonzalez I, Salazar O, Pelaez F, Cummings R, Ha S, Wang J, Singh SB. Angew Chem, Int Ed 2007;46:4684.For platencin A$_1$ isolation, see: (c) Singh SB, Ondeyka JG, Herath KB, Zhang C, Jayasuriya H, Zink DL, Parthasarathy G, Becker JW, Wang J, Soisson SM. Bioorg Med Chem Lett 2009;19:4756. [PubMed: 19581087]

6. (a) Wang J, et al. Nature 2006;441:358. [PubMed: 16710421] (b) Singh SB, Jayasuriya H, Ondeyka JG, Herath KB, Zhang C, Zink DL, Tsou NN, Ball RG, Basilio A, Genilloud O, Diez MT, Vicente F, Pelaez F, Young K, Wang J. J Am Chem Soc 2006;128:11916. [PubMed: 16953632] (c) Singh SB, Herath KB, Wang J, Tsou N, Ball RG. Tetrahedron Lett 2007;48:5429. (d) Herath KB, Attygalle AB, Singh SB. J Am Chem Soc 2007;129:15422. [PubMed: 18034483]

7. For the total synthesis of platensimycin, see: (a) Nicolaou KC, Li A, Edmonds DJ. Angew Chem, Int Ed 2006;45:7086.For formal syntheses of platensimycin, see: (b) Nicolaou KC, Edmonds DJ, Li A,

Tria GS. Angew Chem, Int Ed 2007;46:3942. (c) Zou Y, Chen CH, Taylor CD, Foxman BM, Snider BB. Org Lett 2007;9:1825. [PubMed: 17407302] (d) Nicolaou KC, Tang Y, Wang J. Chem Commun 2007:1922. (e) Li P, Payette JN, Yamamoto H. J Am Chem Soc 2007;129:9534. [PubMed: 17630748] (f) Tiefenbacher K, Mulzer J. Angew Chem, Int Ed 2007;46:8074. (g) Lalic G, Corey EJ. Org Lett 2007;9:4921. [PubMed: 17929829] (h) Nicolaou KC, Pappo D, Tsang KY, Gibe R, Chen DYK. Angew Chem, Int Ed 2008;47:944. (i) Kim CH, Jang KP, Choi SY, Chung YK, Lee E. Angew Chem, Int Ed 2008;47:4009.For a review on the approaches to platensimycin and related analogues, see: (j) Tiefenbacher K, Mulzer J. Angew Chem, Int Ed 2008;47:2548.

8. For total syntheses of platencin, see: (a) Nicolaou KC, Tria GS, Edmonds DJ. Angew Chem, Int Ed 2008;47:1780. (b) Hayashida J, Rawal VH. Angew Chem, Int Ed 2008;47:4373.For formal syntheses of platencin, see: (c) Tiefenbacher K, Mulzer J. Angew Chem, Int Ed 2008;47:6199. (d) Yun SY, Zheng JC, Lee D. Angew Chem, Int Ed 2008;47:6201. (e) Waalboer DCJ, Schaapman MC, Van Delft FL, Rutjes FPJT. Angew Chem, Int Ed 2008;47:6576. (f) Nicolaou KC, Toh QY, Chen DYK. J Am Chem Soc 2008;130:11292. [PubMed: 18665593] (g) Austin KAB, Banwell MG, Willis AC. Org Lett 2008;10:4465. [PubMed: 18798641] (h) Tiefenbacher K, Mulzer J. J Org Chem 2009;74:2937. [PubMed: 19260660] (i) Varseev GN, Maier ME. Angew Chem, Int Ed 2009;48:3685.

9. (a) Nicolaou KC, Lister T, Denton RM, Montero A, Edmonds DJ. Angew Chem, Int Ed 2007;46:4712. (b) Nicolaou KC, Tang Y, Wang J, Stepan AF, Li A, Montero A. J Am Chem Soc 2007;129:14850. [PubMed: 17988130] (c) Nicolaou KC, Stepan AF, Lister T, Li A, Montero A, Tria GS, Turner CI, Tang Y, Wang J, Denton RM, Edmonds DJ. J Am Chem Soc 2008;130:13110. [PubMed: 18771264] (d) Yeung YY, Corey EJ. Org Lett 2008;10:3877. [PubMed: 18665602] (e) Shen HC, Ding F, Singh SB, Parthasarathy G, Soisson SM, Ha SN, Chen X, Kodali S, Wang J, Dorso K, Tata JR, Hammond ML, MacCoss M, Colletti SL. Bioorg Med Chem Lett 2009;19:1623. [PubMed: 19233644] (f) Wang J, Lee V, Sintim HO. Chem Eur J 2009;15:2747. (g) Jang KP, Kim CH, Na SW, Kim H, Kang H, Lee E. Bioorg Med Chem Lett 2009;19:4601. [PubMed: 19604693]

10. (a) Toyota M, Wada T, Fukumoto K, Ihara M. J Am Chem Soc 1998;120:4916. (b) Toyota M, Asano T, Ihara M. Org Lett 2005;7:3929. [PubMed: 16119934] (c) Nonhebel DC. Chem Soc Rev 1993:347. (d) Dowd P, Zhang W. Chem Rev 1993;93:2091.

11. Staben ST, Kennedy-Smith JJ, Huang D, Corkey BK, LaLonde RL, Toste FD. Angew Chem, Int Ed 2006;45:5991.

12. Mander LN, Sethi SP. Tetrahedron Lett 1983;24:5425.

13. (a) Barton DHR, McCombie SW. J Chem Soc Perkin Trans 1 1975:1574. (b) Trost BM, Cramer N, Bernsmann H. J Am Chem Soc 2007;129:3086. [PubMed: 17315880]

14. (a) Park PK, O'Malley SJ, Schmidt DR, Leighton JL. J Am Chem Soc 2006;128:2796. [PubMed: 16506747] (b) Smidt J, Sieber R. Angew Chem 1959;71:261. (c) Takacs JM, Jiang X-T. Curr Org Chem 2003;7:369. (d) Tsuji J. Synthesis 1984:369.

15. Griffith WP, Ley SV, Whitcombe GP, White AD. J Chem Soc Chem Commun 1987:1625.

16. (a) Trost BM, Van Vranken DL. Chem Rev 1996;96:395. [PubMed: 11848758] (a) Sawamura M, Ito Y. Chem Rev 1992;92:857. (b) Trost BM, Crawley ML. Chem Rev 2003;103:2921. [PubMed: 12914486] (c) Trost BM, Fandrick DR. Aldrichimica Acta 2007;40:59.

17. (a) Trost BM, Radinov R, Grenzer EM. J Am Chem Soc 1997;119:7879. (b) Trost BM, Bream RN, Xu J. Angew Chem, Int Ed 2006;45:3109.

18. Varseev and Maier have recently described the use of an allyl enol carbonate to prepare an intermediate similar to 18 in up to 87 % *ee*, see ref. 8i.

19. Asymmetric alkylation reactions using chiral bases or chiral phase transfer catalysts were also considered but not pursued for similar reasons.

20. (a) Kozmin SA, Rawal VH. J Am Chem Soc 1997;119:7165. (b) Janey JM, Iwama T, Kozmin SA, Rawal VH. J Org Chem 2000;65:9059. [PubMed: 11149852] (c) Huang Y, Iwama T, Rawal VH. Org Lett 2002;4:1163. [PubMed: 11922808]

21. (a) Huang Y, Iwama T, Rawal VH. J Am Chem Soc 2000;122:7843. (b) Kozmin SA, Iwama T, Huang Y, Rawal VH. J Am Chem Soc 2002;124:4628. [PubMed: 11971711]

22. Parikh JR, Doering WvE. J Am Chem Soc 1967;89:5505.

23. (a) Kinast G, Tietze LF. Angew Chem, Int Ed 1976;15:239.This reagent is easily prepared on a large scale using a procedure previously reported; see: (b) Danishefsky S, Chackalamannil S, Harrison P, Silvestri M. J Am Chem Soc 1985;107:2474.

24. Tricyclic by-product 21b was characterized by NMR spectroscopic analysis; structures of the other corresponding by-products, such as 21a, 21c–e, were assigned by analogy.

25. CCDC-671740 contains the supplementary crystallographic data for compound (−)-22. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre *via* www.ccdc.cam.ac.uk/data_request/cif.

26. Huang Y, Iwama T, Rawal VH. J Am Chem Soc 2002;124:5950. [PubMed: 12022822] (b) McGilvra JD, Rawal VH. Synlett 2004;13:2440.

27. (a) Toyota M, Asano T, Ihara M. Org Lett 2005;7:3929. [PubMed: 16119934] (b) Taber DF, Wang Y, Stachel SJ. Tetrahedron Lett 1993;34:6209. (c) Hutchins RO, Milewski CA, Maryanoff BE. J Am Chem Soc 1973;95:3662. (d) Zard SZ, Miranda LD. Chem Commun 2001:1068. (e) Taber DE, Wang Y, Pahutski TF Jr. J Org Chem 2000;65:3861. [PubMed: 10864777]

28. (a) Njardarson JT, Biswas K, Danishefsky SJ. Chem Commun 2002:2759. (b) Morrill C, Grubbs RH. J Org Chem 2003;68:6031. [PubMed: 12868943]

29. Garber SB, Kingsbury JS, Gray BL, Hoveyda AH. J Am Chem Soc 2000;122:8168.

30. Hong SH, Sanders DP, Lee CW, Grubbs RH. J Am Chem Soc 2005;127:17160. [PubMed: 16332044]

31. (a) Lindgren BO, Nilsson T. Acta Chem Scand 1973;27:888. (b) Bal BS, Childers WE Jr, Pinnick HW. Tetrahedron 1981;37:2091.

32. Baumhof P, Mazitschek R, Giannis A. Angew Chem, Int Ed 2001;40:3672.

33. CCDC-740150 contains the supplementary crystallographic data for compound (−)-1. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre *via* www.ccdc.cam.ac.uk/data_request/cif.

Figure 1.
Molecular structures of platencin [(−)-**1**] and platensimycin [(−)-**2**].

Figure 2.
Retrosynthetic analysis of platencin [(−)-**1**]

Figure 3.
ORTEP drawing of (−)-**22** derived from X-ray crystallographic analysis (non-hydrogen atoms are shown as 30% ellipsoids).

Figure 4.
Molecular structures of Cr(III)- and Co(III)-salen catalysts **32** and **40**.

Figure 5.
ORTEP drawing of (−)-**1** derived from X-ray crystallographic analysis (non-hydrogen atoms are shown as 30% ellipsoids).

Scheme 1.

Synthesis of Racemic Tricyclic Enone [(±)]-5[a]

[a]Reagents and conditions: a) LiHMDS (1.0 M in THF, 1.2 equiv), methyl cyanoformate (1.2 equiv), THF, −78 → 0 °C, 2 h, 92%; b) NaH (1.5 equiv), allyl bromide (1.5 equiv), THF, 0 → 25 °C, 2 h, 79%; c) LiAlH₄ (1.0 M in THF, 1.2 equiv), Et₂O, 0 → 25 °C, 3 h; then HCl (2 M in MeOH, 6.0 equiv), 25 °C, 16 h, 82%; d) PMBOC(NH)CCl₃ (2.0 equiv), TsOH (0.1 equiv), CH₂Cl₂, 0 → 25 °C, 2.5 h, 85%; e) TBSOTf (2.5 equiv), Et₃N (4.0 equiv), THF, 0 °C, 1 h, 91%; f) Pd(OAc)₂ (0.1 equiv), O₂ (balloon), DMSO, 45 °C, 12 h, 85%; g) CuBr•Me₂S (2.0 equiv), allyl magnesium chloride (1.7 M in THF, 4.0 equiv), THF, −78 → −40 °C, 2 h, 86%; h) NaBH₄ (2.5 equiv), MeOH, −5 → 25 °C, 30 min, 97%; i) KHMDS (0.5 M in toluene, 5.0 equiv), CS₂ (10.0 equiv), MeI (10.0 equiv), THF, −78 → 25 °C, 2.5 h, 92%; j) n-Bu₃SnH (2.0 equiv), AIBN (0.08 equiv), toluene, 110 °C, 8 h, 92%; k) PdCl₂ (0.25 equiv), CuCl (1.5 equiv), O₂ (balloon), DMF:H₂O (6.6:1), 25 °C, 24 h, 81%; l) DDQ (1.2 equiv), CH₂Cl₂:H₂O 20:1, 25 °C, 1 h, 53%; m) TPAP (0.03 equiv), NMO (6.5 equiv), CH₂Cl₂, 25 °C, 4 h, 54%; n) NaOH (6.0 equiv), EtOH, 25 °C, 8 h, 99%.

Scheme 2.

Construction of Diene **26** and Dienophiles **30** and **31**[a]

[a]Reagents and conditions: a) **25** (1.0 equiv), **24** (2.0 equiv), TsOH (0.05 equiv), CHCl$_3$, 65 °C, 24 h, 89%; b) TBSOTf (1.1 equiv), Et$_3$N (3.0 equiv), Et$_2$O, −78 → 0 °C, 1 h, 96%; c) py•SO$_3$ (2.0 equiv), DMSO (5.0 equiv), Et$_3$N (5.0 equiv), CH$_2$Cl$_2$, 25 °C, 2 h; then CH$_2$NMe$_2$Cl (**29**) (1.5 equiv), 25 °C, 12 h, R = H, 53%, R = TMS, 92%.

Scheme 3.
First Generation Catalytic Asymmetric Synthesis of Tricyclic Enone [(+)-**5**][a]
[a]Reagents and conditions: a) **30** (1.0 equiv), **26** (1.7 equiv), **32** (0.05 equiv), 4 Å M.S., CH$_2$Cl$_2$, −60 °C, 60 h, 92%; b) LiAlH$_4$ (1.0 M in THF, 1.5 equiv), Et$_2$O, −78 → −40 °C, 2 h; then HCl (2 M in MeOH, 10.0 equiv), 25 °C, 16 h, 63%; c) SEMCl (1.2 equiv), Et$_3$N (4.0 equiv), 4-DMAP (0.1 equiv), THF, 70 °C, 16 h, 94%; d) TIPSOTf (1.5 equiv), Et$_3$N (3.0 equiv), −78 → 0 °C, 1 h, 97%; e) [AuCl(PPh$_3$)] (0.02 equiv), AgBF$_4$ (0.02 equiv), toluene/MeOH (10:1), 25 °C, 30 min, 94%; f) allyl magnesium chloride (1.7 M in THF, 4.0 equiv), CuBr•Me$_2$S (2.0 equiv), THF, −78 °C, 1.5 h, 74%; g) NaBH$_4$ (2.5 equiv), MeOH, −5 → 25 °C, 1 h, 97%; h) CS$_2$ (10.0 equiv), KHMDS (0.5 M in toluene, 5.0 equiv), MeI (5.0 equiv), THF, −78 → 25 °C, 2.5 h, 100%; i) n-Bu$_3$SnH (2.0 equiv), AIBN (0.08 equiv), toluene, 100 °C, 20 min, 92%; j) PdCl$_2$ (0.25 equiv), CuCl (1.5 equiv), O$_2$ (balloon), DMF/H$_2$O (6.6:1), 25 °C, 24 h, 50% (2 steps); k) TASF (10.0 equiv), DMPU, 80 °C, 1.5 h, 63% (84% based on 25% recovered starting material); l) TPAP (0.03 equiv), NMO (6.5 equiv), CH$_2$Cl$_2$, 25 °C, 4 h, 54%; m) NaOH (6.0 equiv), EtOH, 25 °C, 8 h, 99%.

Scheme 4.
Second Generation Catalytic Asymmetric Synthesis of Tricyclic Enone [(+)-**5**][a]
[a]Reagents and conditions: a) **31** (1.0 equiv), **26** (1.05 equiv), **40** (0.1 mol %), 4 Å M.S., CH$_2$Cl$_2$, 0 °C, 97%; b) LiAlH$_4$ (1.0 M in THF, 1.5 equiv), Et$_2$O, −78 → −40 °C, 2 h; then K$_2$CO$_3$ (5.0 equiv), MeOH (50 equiv), 25 °C, 5 h; then HCl (4 M in MeOH, 20.0 equiv), 25 °C, 16 h, 92%; c) TBSCl (1.5 equiv), Et$_3$N (4.0 equiv), 4-DMAP (0.1 equiv), CH$_2$Cl$_2$, 45 °C, 16 h; then TBSOTf (1.5 equiv), 0 °C, 4 h, 97%; d) [AuCl(PPh$_3$)] (0.02 equiv), AgBF$_4$ (0.02 equiv), toluene/MeOH (10:1), 25 °C, 30 min, 95%; e) CuBr•Me$_2$S (2.0 equiv), allyl magnesium chloride (1.7 M in THF, 4.0 equiv), THF, −78 → −40 °C, 1.5 h; then 2 M aq. HCl (10.0 equiv), 25 °C, 4 h, 85%; f) TsNHNH$_2$ (1.2 equiv), TsOH (0.1 mol %), CH$_2$Cl$_2$, 45 °C, 1 h; then

$NaBH_4$ (2.0 equiv), MeOH (7.0 equiv), 45 °C, 74%; g) DMP (2.0 equiv), pyridine (0.1 equiv), CH_2Cl_2, 25 °C, 1.5 h, 90%; h) $PdCl_2$ (0.25 equiv), CuCl (1.5 equiv), O_2 (balloon), DMF/H_2O (6.6:1), 25 °C, 24 h, 90%; i) NaOH (6.0 equiv), EtOH, 25 °C, 8 h, 99%.

Scheme 5.
bis-Silylation of Hydroxy Enone (−)-**16**[a]
[a] Reagents and conditions: a) TBSOTf (2.5 equiv), Et$_3$N (5.0 equiv), CH$_2$Cl$_2$, −78 → 0 °C, 1 h; b) TBSCl (1.5 equiv), Et$_3$N (4.0 equiv), 4-DMAP (0.1 equiv), CH$_2$Cl$_2$, 45 °C, 16 h; then TBSOTf (1.5 equiv), 0 °C, 4 h, 97%.

Scheme 6.
Alkylation of Tricyclic Enone (+)-**5** and Construction of Carboxylic Acid (+)-**4**[a]
[a]Reagents and conditions: a) KHMDS (0.5 M in toluene, 1.1 equiv), MeI (8.0 equiv), THF/HMPA (4:1), −78 → 0 °C, 2 h, 90%; b) KHMDS (0.5 M in toluene, 4.0 equiv), allyl iodide (8.0 equiv), THF/HMPA (4:1), −78 → 0 °C, 3 h, 86%; c) **48** (5.0 equiv), Hoveyda–Grubbs II cat. **49** (0.1 equiv), benzoquinone (0.1 equiv), benzene, 70 °C, 1 h, 75%; d) Me$_3$NO (5.0 equiv), THF, 70 °C, 1 h, 63%; e) NaClO$_2$ (3.0 equiv), NaH$_2$PO$_4$ (5.0 equiv), 2-methyl-2-butene (10.0 equiv), *t*-BuOH/H$_2$O (1:1), 25 °C, 20 min, 82%.

Scheme 7.
Synthesis of Carboxylic Acid (+)-**4** *via* Conjugate Addition[a]
[a]Reagents and conditions: a) *tert*-butyl acrylate (2.0 equiv), KO*t*-Bu (1.0 M in *t*-BuOH, 2.0 equiv), THF, 25 °C, 30 min, 92% (*ca.* 2:1 dr); b) LiOH (1 N aqueous):MeOH (1:1), 50 °C, 6 h, 97%.

**Scheme 8.**
Preparation of Aniline Derivative **3**[a]
[a]Reagents and conditions: a) TMSEOH (14.8 equiv), *n*-Bu$_2$SnO (1.5 equiv), 70 °C, 3 h, 61%; b) H$_2$ (balloon), 10% Pd/C (0.05 equiv), AcOH (1.0 equiv), EtOAc/MeOH (5:1), 25 °C, 15 h, 100%.

Scheme 9.
Completion of the Total Synthesis of Platencin [(−)-**1**][a]
[a] Reagents and conditions: a) **3** (3.2 equiv), HATU (3.2 equiv), Et₃N (4.2 equiv), DMF, 25 °C, 14 h, 61%; b) TASF (2.0 equiv), DMF, 40 °C, 40 min, 93%.

Table 1

Optimization of the Catalytic Asymmetric Diels–Alder Reaction[a]

Entry	Dienophile	Diene (equiv)	Catalyst (mol %)	Temp. (°C)	Time (h)	Yield (%)	ee (%)
1	**30**	1.5	**32** (5)	25	60	85	75
2	**30**	1.5	**32** (5)	–40	60	87	85
3	**30**	2.0	**32** (5)	–60	60	**92**	**93**[b]
4	**30**	1.8	**40** (5)	0	2	79	76
5	**31**	1.8	**40** (5)	0	1.5	92	93
6	**31**	1.5	**40** (1)	0	0.5	93	94
7	**31**	1.1	**40** (0.1)	0	0.5	**97**	**96**
8	**31**	1.5	none	25	0.5	5	0

[a]Reactions were carried out on 0.1–1.0 mmol scale with 1.0 equiv. dienophile **30** or **31** in the presence of 4 Å M. S. in CH$_2$Cl$_2$.

[b]Enantiomeric excess (*ee*) ranged from 86–93%.

Table 2

Effect of Protecting Group on the Radical Deoxygenation Reaction[a]

Entry	R (Compound)	Yield (%)	Product ratio 6:21[b]
1	MOM (**9c**)	93	5.4:1 (**6c**)
2	SEM (**9b**)	92	5.5:1 (**6b**)
3	PMB (**9a**)	92	4:1 (**6a**)
4	Ac (**9d**)	71	1:1.5 (**6d**)
5	Piv (**9e**)	65	1:2 (**6e**)

[a]Reactions were carried out on 0.01 mmol scale with 2.0 equiv. *n*-Bu3SnH and 0.08 equiv AIBN in toluene at 100 °C.

[b]Ratios were determined by ^{1}H NMR (500 MHz) spectroscopic analysis.

Table 3

Optimization of the Radical-Based Conversion of Hydrazones **12** to [2.2.2] Bicyclo Systems **6**[a]

Entry	R (compound)	Reductant (equiv)	Solvent	Temp. (°C)	Yield (%)
1	MOM (**12a**)	$NaBH_3CN$ (3.8)[b]	THF	80	0[c]
2	PMB (**12b**)	$NaBH_3CN$ (3.8)[b]	THF	80	0[c]
3	Piv (**12c**)	$NaBH_3CN$ (3.8)[b]	THF	80	0[c]
4	SEM (**12d**)	$NaBH_4$ (1.4)	TiHF	90	0[c]
5	SEM (**12d**)	$NaBH(OAc)_3$ (4.0)	DCE:AcOH (9:1)	100	0[d]
6	SEM (**12d**)	$NaBH_4$ (8.0)	CH_2Cl_2:MeOH (1:1)	45	50
7	SEM (**12d**)	$NaBH_4$ (8.0)	THF:MeOH (1:1)	70	47
8	SEM (**12d**)	$NaBH_4$ (8.0)	CH_2Cl_2:MeOH (1:1)	25	0[c]
9	SEM (**12d**)	$NaBH_4$ (8.0)	CH_2Cl_2:MeOH (20:1)	45	55
10	SEM (**12d**)	$NaBH_4$ (8.0)	CH_2Cl_2:EtOH (20:1)	45	60
11	SEM (**12d**)	$NaBH_4$ (2.0 × 3)	CH_2Cl_2:MeOH (20:1)	45	70
12	H (**12**)	$NaBH_4$ (2.0 × 4)	CH_2Cl_2:MeOH (20:1)	45	74 (**6f**)

[a]Reactions were carried out on 0.1–1.0 mmol scale.

[b]With 3.8 equiv. $ZnCl_2$.

[c]Only decomposition observed.

[d]No reaction observed.